LXRX vs. GERN

Last updated Apr 2, 2026

Compare and contrast key facts about Lexicon Pharmaceuticals, Inc. (LXRX) and Geron Corporation (GERN).

Performance

LXRX vs. GERN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Lexicon Pharmaceuticals, Inc. (LXRX) and Geron Corporation (GERN). The values are adjusted to include any dividend payments, if applicable.

LXRX vs. GERN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
LXRX Lexicon Pharmaceuticals, Inc.	42.61%	55.72%	-51.73%	-19.90%	-51.52%	15.20%	-17.59%	-37.50%	-32.79%	-28.56%
GERN Geron Corporation	25.76%	-62.71%	67.77%	-12.81%	98.36%	-23.27%	16.91%	36.00%	-44.44%	-13.04%

Fundamentals

EPS LXRX : -$0.19 GERN : -$0.13
PS Ratio LXRX : 8.41 GERN : 6.02
Total Revenue (TTM) LXRX : $70.86M GERN : $183.88M
Gross Profit (TTM) LXRX : $44.68M GERN : $158.07M
EBITDA (TTM) LXRX : -$48.31M GERN : -$39.32M

Returns By Period

In the year-to-date period, LXRX achieves a 42.61% return, which is significantly higher than GERN's 25.76% return. Over the past 10 years, LXRX has underperformed GERN with an annualized return of -18.37%, while GERN has yielded a comparatively higher -5.75% annualized return.

LXRX

• 1D: 5.13%
• 1M: 5.13%
• YTD: 42.61%
• 6M: 16.31%
• 1Y: 253.37%
• 3Y*: -12.28%
• 5Y*: -22.51%
• 10Y*: -18.37%

GERN

• 1D: 11.41%
• 1M: 7.10%
• YTD: 25.76%
• 6M: 17.73%
• 1Y: 12.16%
• 3Y*: -8.54%
• 5Y*: 0.49%
• 10Y*: -5.75%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

LXRX vs. GERN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LXRX

LXRX Risk / Return Rank: 93
LXRX Sharpe Ratio Rank: 95
LXRX Sortino Ratio Rank: 92
LXRX Omega Ratio Rank: 88
LXRX Calmar Ratio Rank: 97
LXRX Martin Ratio Rank: 95

GERN

GERN Risk / Return Rank: 46
GERN Sharpe Ratio Rank: 47
GERN Sortino Ratio Rank: 49
GERN Omega Ratio Rank: 45
GERN Calmar Ratio Rank: 44
GERN Martin Ratio Rank: 43

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LXRX vs. GERN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Lexicon Pharmaceuticals, Inc. (LXRX) and Geron Corporation (GERN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LXRX	GERN	Difference
Sharpe ratio Return per unit of total volatility	2.82	0.18	+2.64
Sortino ratio Return per unit of downside risk	3.11	0.78	+2.33
Omega ratio Gain probability vs. loss probability	1.38	1.09	+0.29
Calmar ratio Return relative to maximum drawdown	7.51	0.13	+7.38
Martin ratio Return relative to average drawdown	16.40	0.24	+16.16
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LXRX vs. GERN - Sharpe Ratio Comparison

The current LXRX Sharpe Ratio is 2.82, which is higher than the GERN Sharpe Ratio of 0.18. The chart below compares the historical Sharpe Ratios of LXRX and GERN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	LXRX	GERN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.82	0.18	+2.64
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.23	0.01	-0.24
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.19	-0.07	-0.12
Sharpe Ratio (All Time) Calculated using the full available price history	-0.18	-0.06	-0.12

Correlation

The correlation between LXRX and GERN is 0.35, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

LXRX vs. GERN - Dividend Comparison

Neither LXRX nor GERN has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

LXRX vs. GERN - Drawdown Comparison

The maximum LXRX drawdown since its inception was -99.91%, roughly equal to the maximum GERN drawdown of -98.73%. Use the drawdown chart below to compare losses from any high point for LXRX and GERN.

Drawdown Indicators

	LXRX	GERN	Difference
Max Drawdown Largest peak-to-trough decline	-99.91%	-98.73%	-1.18%
Max Drawdown (1Y) Largest decline over 1 year	-34.09%	-33.95%	-0.14%
Max Drawdown (5Y) Largest decline over 5 years	-95.25%	-78.98%	-16.27%
Max Drawdown (10Y) Largest decline over 10 years	-98.48%	-86.09%	-12.39%
Current Drawdown Current decline from peak	-99.50%	-97.62%	-1.88%
Average Drawdown Average peak-to-trough decline	-93.16%	-86.08%	-7.08%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.60%	18.31%	-2.71%

Volatility

LXRX vs. GERN - Volatility Comparison

The current volatility for Lexicon Pharmaceuticals, Inc. (LXRX) is 17.27%, while Geron Corporation (GERN) has a volatility of 22.47%. This indicates that LXRX experiences smaller price fluctuations and is considered to be less risky than GERN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LXRX	GERN	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.27%	22.47%	-5.20%
Volatility (6M) Calculated over the trailing 6-month period	60.57%	47.60%	+12.97%
Volatility (1Y) Calculated over the trailing 1-year period	90.39%	68.68%	+21.71%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	97.49%	82.49%	+15.00%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	96.86%	78.02%	+18.84%

Financials

LXRX vs. GERN - Profitability Comparison

The chart below illustrates the profitability comparison between Lexicon Pharmaceuticals, Inc. and Geron Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

LXRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Lexicon Pharmaceuticals, Inc. reported a gross profit of 14.17M and revenue of 14.18M. Therefore, the gross margin over that period was 99.9%.

GERN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Geron Corporation reported a gross profit of 46.71M and revenue of 48.02M. Therefore, the gross margin over that period was 97.3%.

LXRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Lexicon Pharmaceuticals, Inc. reported an operating income of -12.19M and revenue of 14.18M, resulting in an operating margin of -85.9%.

GERN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Geron Corporation reported an operating income of -10.79M and revenue of 48.02M, resulting in an operating margin of -22.5%.

LXRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Lexicon Pharmaceuticals, Inc. reported a net income of -12.77M and revenue of 14.18M, resulting in a net margin of -90.0%.

GERN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Geron Corporation reported a net income of -31.14M and revenue of 48.02M, resulting in a net margin of -64.9%.